DEGS1 and acute myeloid leukemia: Given our findings that JTE-013 inhibits Des1 and SK1/2 when employed at 10 μM, we re-examined our previous findings, that had suggested targeting S1P2 (with JTE-013) induced Mcl-1 degradation and cell death in AML cells13.